Drug Information

Drug General Information
Drug ID
D00FGR
Former ID
DPR000076
Drug Name
Miltefosine
Synonyms
HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
Drug Type
Small molecular drug
Indication Leishmaniasis [ICD10:B55.0] Approved [533123]
Visceral leishmaniasis [ICD9: 85; ICD10:B55.0] Phase 2 [537364]
Therapeutic Class
Antifungal Agents
Company
Aeterna Zentaris
Structure
Download
2D MOL

3D MOL
Formula
C21H46NO4P
Canonical SMILES
CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C
InChI
1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
InChIKey
PQLXHQMOHUQAKB-UHFFFAOYSA-N
CAS Number
CAS 58066-85-6
PubChem Compound ID
3599
PubChem Substance ID
226520, 484338, 4562729, 8137426, 8152270, 12014266, 14781695, 17396669, 26612907, 26680623, 26749044, 26749045, 26759174, 29222725, 49747674, 49748182, 49966181, 50107510, 53788176, 53800667, 57321887, 75270305, 91010630, 92124640, 92308871, 93620194, 103186893, 103942430, 104303974, 118846353, 124633439, 124633952, 124637845, 125334625, 126592939, 126645243, 126664051, 131319651, 134339527, 134358597, 135030585, 136946455, 137106670, 139786526, 144075829, 144116216, 144205019, 152054305, 162009789, 162173181
SuperDrug ATC ID
L01XX09
SuperDrug CAS ID
cas=058066856
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Phospholipase A2 Target Info Inhibitor [537364]
BioCyc Pathway Phospholipases
KEGG Pathway Glycerophospholipid metabolism
Ether lipid metabolism
Arachidonic acid metabolism
Linoleic acid metabolism
alpha-Linolenic acid metabolism
Metabolic pathways
Ras signaling pathway
Vascular smooth muscle contraction
Pancreatic secretion
Fat digestion and absorption
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
Reactome Acyl chain remodelling of PC
Acyl chain remodelling of PE
Acyl chain remodelling of PI
WikiPathways Glycerophospholipid biosynthesis
References
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
Ref 537364Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. Epub 2009 May 7.
Ref 537364Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. Epub 2009 May 7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.